Jaguar Health Inc (NASDAQ:JAGX) has gone public over its commercial, educational and product development programs as well the 2017 results of Mytesi sales. The pharmaceutical company reported that its monthly Mytesi sales for the period August 1, 2017, through December 31, 2017, were relatively good having obtained than 78% increase. The company had previously merged with Napo Pharmaceuticals, a move, which played a significant role in obtaining the said sales.
The merger was able to tap into the expertise of Napo’s highly trained Mytesi sales representatives. The nine employees have previously worked for drugmaker Bristol-Myers Squibb Co (NYSE: BMY), thus they have extensive experience in drug sales.
The U.S. geographies have the highest potential to drive Mytesi business
Jaguar’s President and CEO, Lisa Conte notes that Napo has such a high-potential prescriber base of close to 3,500 high-volume ART prescribers. The figure is in addition to the 1,500 gastroenterologists who address the needs of people living with HIV. The company’s sales force is located in the U.S. geographies, which is said to have the highest potential to drive Mytesi business.
Apparently, there was an increase of in new Mytesi prescribers among gastroenterologists and HIV specialists by 86% and 8% respectively. There was also a 9.5% monthly increase in the number of Mytesi prescriptions written by physicians in the August 1, 2017, through December 31, 2017, period.
The expansion of the Mytesi related commercial, educational and development initiatives
Conte outlines that the merger will be instrumental in reaching out to the neglected activities, which help to provide proper healthcare. This includes the creation and rolling out of direct-to-consumer advertising campaigns, educational and development initiatives among others.
Napo will also be supporting congenital diarrheal disorders (CDDs). Though they are rare, the genetic defects occur in early infancy and are inherited as autosomal recessive traits. The company will be working hand in hand with Dr. Mohamad Miqdady, Chief of Pediatric Gastroenterology and is based at Sheikh Khalifa Medical City (SKMC) in Abu Dhabi.
Meanwhile, the company has joined the HIV community in mourning the demise of Dr. Mathilde Krim, the Cofounder and Chairperson of the American Foundation for AIDS Research (amfAR). As a geneticist and virologist Krim has left a prestigious legacy of battling HIV.